Affinity Asset Advisors LLC Buys 101,747 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Affinity Asset Advisors LLC grew its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 912,000 shares of the company’s stock after acquiring an additional 101,747 shares during the quarter. Nurix Therapeutics comprises approximately 2.2% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 9th biggest position. Affinity Asset Advisors LLC owned about 1.86% of Nurix Therapeutics worth $19,033,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of NRIX. Quest Partners LLC acquired a new position in Nurix Therapeutics in the 4th quarter valued at about $59,000. GAMMA Investing LLC increased its stake in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after acquiring an additional 3,424 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in Nurix Therapeutics in the first quarter valued at $123,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after purchasing an additional 3,793 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth $158,000.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $24.28 on Wednesday. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $26.31. The company has a 50 day moving average price of $22.99 and a 200 day moving average price of $18.40.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 9,050 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $24.94, for a total transaction of $225,707.00. Following the completion of the transaction, the insider now owns 24,592 shares in the company, valued at $613,324.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the sale, the chief financial officer now directly owns 31,002 shares in the company, valued at $781,870.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christine Ring sold 9,050 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $24.94, for a total value of $225,707.00. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at $613,324.48. The disclosure for this sale can be found here. Insiders have sold 59,815 shares of company stock valued at $1,416,751 in the last 90 days. 7.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

NRIX has been the topic of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price on the stock. Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a report on Friday, July 12th. JPMorgan Chase & Co. upped their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Barclays increased their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, Royal Bank of Canada increased their target price on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Friday, July 12th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.